Essential hypertension

被引:393
作者
Staessen, JA
Wang, JG
Bianchi, G
Birkenhäger, WH
机构
[1] Katholieke Univ Leuven, Dept Mol Cardiovasc Onderzoek, Studiecoordinatiectr, Louvain, Belgium
[2] Univ Vita Salute, Dipartimento Sci & Technol Biomed, Osped San Raffaele, Div Nefrol Dialisi & Ipertens, Milan, Italy
[3] Erasmus Univ, Rotterdam, Netherlands
关键词
D O I
10.1016/S0140-6736(03)13302-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hypertension is a frequent, chronic, age-related disorder, which often entails debilitating cardiovascular and renal complications. Blood pressure is usually noted in combination with other cardiovascular risk factors. Diagnosis of hypertension increasingly relies on automated techniques of blood pressure measurement. The pathophysiology of essential hypertension depends on the primary or secondary inability of the kidney to excrete sodium at a normal blood pressure. The central nervous system, endocrine factors, the large arteries, and the microcirculation also have roles in the disorder. Although monogenic forms of blood pressure dysregulation exist, hypertension mostly arises as a complex quantitative trait that is affected by varying combinations of genetic and environmental factors. Non-pharmacological strategies can reduce blood pressure. Antihypertensive drug treatment diminishes the complications of hypertension. The concept that a few major genes will provide the final clue to the pathogenesis of essential hypertension is an oversimplification that contradicts the heterogeneous nature of this disorder. Further integration of genetic, molecular, clinical, and epidemiological research could disclose subsets of patients in whom specific combinations of genetic and environmental factors raise blood pressure, and might lead to more individualised treatment.
引用
收藏
页码:1629 / 1641
页数:13
相关论文
共 146 条
[11]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[12]   Home self blood pressure measurement in general practice - The SMART study [J].
Chatellier, G ;
DutreyDupagne, C ;
Vaur, L ;
Zannad, F ;
Genes, N ;
Elkik, F ;
Menard, J .
AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (07) :644-652
[13]   BLOOD-PRESSURE, ANTIHYPERTENSIVE DRUG-TREATMENT AND THE RISKS OF STROKE AND OF CORONARY HEART-DISEASE [J].
COLLINS, R ;
MACMAHON, S .
BRITISH MEDICAL BULLETIN, 1994, 50 (02) :272-298
[14]   Genome scan among Nigerians linking blood pressure to chromosomes 2, 3, and 19 [J].
Cooper, RS ;
Luke, A ;
Zhu, XF ;
Kan, DH ;
Adeyemo, A ;
Rorimi, C ;
Bouzekri, N ;
Ward, R .
HYPERTENSION, 2002, 40 (05) :629-633
[15]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[16]   Hypoxia triggers release of an endogenous inhibitor of Na+-K+-ATPase from midbrain and adrenal [J].
De Angelis, C ;
Haupert, GT .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 1998, 274 (01) :F182-F188
[17]   THE EFFECT OF INCREASED SALT INTAKE ON BLOOD-PRESSURE OF CHIMPANZEES [J].
DENTON, D ;
WEISINGER, R ;
MUNDY, NI ;
WICKINGS, EJ ;
DIXSON, A ;
MOISSON, P ;
PINGARD, AM ;
SHADE, R ;
CAREY, D ;
ARDAILLOU, R ;
PAILLARD, F ;
CHAPMAN, J ;
THILLET, J ;
MICHEL, JB .
NATURE MEDICINE, 1995, 1 (10) :1009-1016
[18]   Nervous kidney - Interaction between renal sympathetic nerves and the renin-angiotensin system in the control of renal function [J].
DiBona, GF .
HYPERTENSION, 2000, 36 (06) :1083-1088
[19]   Optimisation of antihypertensive treatment by crossover rotation of four major classes [J].
Dickerson, JEC ;
Hingorani, AD ;
Ashby, MJ ;
Palmer, CR ;
Brown, MJ .
LANCET, 1999, 353 (9169) :2008-2013
[20]   Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAL randomised trial [J].
Dickstein, K ;
Kjekshus, J .
LANCET, 2002, 360 (9335) :752-760